102653-36-1

Basic information

• Product Name: 3-bromonaphthalene-2,7-diol
• Synonyms: 3-bromonaphthalene-2,7-diol
• CAS NO: 102653-36-1
• Molecular Weight: 239.068
• Mol File: 102653-36-1.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 3-bromonaphthalene-2,7-diol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-bromonaphthalene-2,7-diol(102653-36-1)
• EPA Substance Registry System: 3-bromonaphthalene-2,7-diol(102653-36-1)

Safety Data

• Hazardous Substances Data: 102653-36-1(Hazardous Substances Data)

Usage

General Description

3-Bromonaphthalene-2,7-diol is a chemical compound with the molecular formula C10H7BrO2. It is a type of naphthalene derivative and is commonly used in the field of organic chemistry as a starting material for the synthesis of various other compounds. It is known for its unique molecular structure and is often used in research and development of new chemical processes. 3-bromonaphthalene-2,7-diol has potential applications in pharmaceuticals, agrochemicals, and other industries due to its versatile chemical properties. It is important to handle this chemical with care, as it can be hazardous if not properly managed.

Upstream product

• 582-17-2 2,7-Dihydroxynaphthalene 
• 102154-14-3 1,3-dibromo-naphthalene-2,7-diol 
• 96965-78-5 1,6-dibromo-2,7-dihydroxynaphthalene 

Downstream Products

• 1019777-26-4 2-bromo-3,6-dibenzyloxynaphthalene 
• 1632161-74-0 benzyl 4-[[7-(4-benzyloxy-4-oxo-butoxy)-6-bromo-2-naphthyl]oxy]butanoate 
• 1632161-66-0 C₆₀H₈₃N₁₁O₁₆ 
• 1632161-65-9 C₆₃H₈₉N₁₁O₁₈ 
• 1632161-64-8 C₆₆H₉₃N₁₁O₁₈ 
• 1632161-89-7 4-[[6-[2-(benzyloxycarbonylamino)ethynyl]-7-(4-hydroxy-4-oxo-butoxy)-2-naphthyl]oxy]butanoic acid 
• 1632161-88-6 ethyl4-[[6-[2-[bis(benzyloxycarbonyl)amino]ethynyl]-7-(4-ethoxy-4-oxo-butoxy)-2-naphthyl]oxy]butanoate 
• 1632161-63-7 C₄₈H₆₁N₉O₁₂ 
• 1632161-86-4 benzyl 4-[[7-(4-benzyloxy-4-oxo-butoxy)-6-[3-(dimethylamino)prop-1-ynyl]-2-naphthyl]oxy]butanoate 
• 1632161-85-3 4-[[6-[[2-(4-benzyloxycarbonylpiperazin-1-yl)acetyl]amino]-7-(4-hydroxy-4-oxo-butoxy)-2-naphthyl]oxy]butanoic acid 
• 1632161-84-2 ethyl 4-[2-[[3,6-bis(4-ethoxy-4-oxo-butoxy)-2-naphthyl]amino]-2-oxo-ethyl]piperazine-1-carboxylate 
• 1632161-80-8 benzyl 4-[[7-(4-benzyloxy-4-oxo-butoxy)-6-[(2-chloroacetyl)amino]-2-naphthyl]oxy]butanoate 
• 1632161-78-4 benzyl 4-[[6-amino-7-(4-benzyloxy-4-oxo-butoxy)-2-naphthyl]oxy]butanoate 
• 1632161-62-6 C₅₁H₆₇N₉O₁₄ 

Relevant articles and documents

Total Syntheses of FR-901235, Auxarthrones A-D, and Lamellicolic Anhydride

In our previous study, an unusual rearrangement reaction was discovered whereby dinaphthyl ketones with three hydroxy groups at restricted positions were transformed into a phenalenone ring and a benzene ring. Using the rearrangement as a key reaction, the first total syntheses of FR-901235 and auxarthrones A-D from an unstable triketone common intermediate are described. Furthermore, lamellicolic anhydride was synthesized from the triketone. This conversion is part of the putative biosynthetic pathway and was achieved experimentally for the first time.

Introduction of polar groups on the naphthalene scaffold of molecular tongs inhibiting wild-type and mutated HIV-1 protease dimerization

A new series of naphthalene-based molecular tongs containing polar groups at the 3-position of the naphthalene scaffold was synthesized and its anti-dimerization activity was evaluated against HIV-1 protease. The polar groups were introduced mainly via me

ORGANIC COMPOUNDS

Compounds of the formula are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat and/or prevent cancer (such as prostate or breast cancer), osteoporosis, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.